Monés J, Rubin G S
Instituto de Microcirugia Ocular de Barcelona, Barcelona, Spain.
Eye (Lond). 2005 Nov;19(11):1142-50. doi: 10.1038/sj.eye.6701717.
Although visual acuity is the most frequently used primary outcome measure in clinical trials of treatments for choroidal neovascularisation (CNV) due to age-related macular degeneration (AMD), contrast sensitivity may provide valuable additional information. This paper reviews the evidence for using contrast sensitivity as a measure of visual function and as an outcome measure in clinical trials in patients with subfoveal CNV due to AMD.
Medline database searches were performed to retrieve relevant articles on contrast sensitivity. In addition, articles were included from the authors' knowledge of the literature and from the reference lists of retrieved articles.
The published literature demonstrates that contrast sensitivity is an important measure of visual function in patients with subfoveal CNV due to AMD. Most clinical trials of treatments for CNV due to AMD have reported visual acuity as the primary outcome. However, there is evidence that treatment (such as verteporfin therapy) may also provide additional benefits in terms of contrast sensitivity. These benefits may not be completely characterised by measurement of visual acuity alone.
The inclusion of contrast sensitivity as an outcome measure in studies of patients with CNV due to AMD may provide a more complete understanding of the effects of treatment on visual function and the likely benefits for patients.
尽管视力是年龄相关性黄斑变性（AMD）所致脉络膜新生血管（CNV）治疗临床试验中最常用的主要结局指标，但对比敏感度可能提供有价值的额外信息。本文综述了将对比敏感度用作视觉功能指标以及AMD所致中心凹下CNV患者临床试验结局指标的证据。
检索Medline数据库以获取关于对比敏感度的相关文章。此外，纳入了作者从文献知识以及检索文章的参考文献列表中获取的文章。
已发表的文献表明，对比敏感度是AMD所致中心凹下CNV患者视觉功能的重要指标。大多数AMD所致CNV治疗的临床试验都将视力作为主要结局进行报告。然而，有证据表明治疗（如维替泊芬治疗）在对比敏感度方面也可能带来额外益处。这些益处可能无法仅通过视力测量完全体现。
在AMD所致CNV患者研究中纳入对比敏感度作为结局指标，可能会更全面地了解治疗对视觉功能的影响以及对患者可能带来的益处。
